Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536821 · ClinicalTrials.gov registry record
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)
A clinical trial of Parkinson Disease, sponsored by Indiana University.
- Completed
- Registry status
- 81
- Enrollment target
- 10
- Study locations
NCT01536821: Completed study of Parkinson Disease, sponsored by Indiana University.
NCT01536821 is a study of Parkinson Disease that has completed, run by Indiana University. The registered enrollment target is 81 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01536821, a study of Parkinson Disease, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an affiliated research facility closest to their home.
Conditions Studied
Study Locations (10)
Florida
- Cleveland Clinic Florida - Weston
Indiana
- Indiana University Medical Center - Indianapolis
Iowa
- University of Iowa Hospitals - Iowa City
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- University of Maryland School of Medicine - Baltimore
Nebraska
- University of Nebraska - Omaha
New York
- Beth Israel Medical Center - New York
Ohio
- Medical University of Ohio - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-12 |
What the finished NCT01536821 record still lists
NCT01536821 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01536821 lists 10 locations in 10 states (Florida, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT01536821 about?
NCT01536821 is a clinical study titled "PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)". The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an af...
What is the current status of trial NCT01536821?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2011-05. Estimated completion is 2013-12.
What conditions does trial NCT01536821 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT01536821?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01536821 being conducted?
This trial has 10 study locations across Florida, Indiana, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01536821's enrollment target sits among peer trials
81 104th of 297 higher than 194 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia